KISUNLA™ Referral Form





Fax Completed Form To:

Phone:

		DAT	IENT INFORM	MOLTA				
Patient Name:		PAI	IENT INFORM	ATION		Date of Birth:		
Referral Date:		New Referral	Updated Order	Order Re	newal	Date of birth.		
Address: City/State/Zip:								
Home Phone: Cell Phone:			e. (y, 5 tate, 2.			Work Phone:		
Secondary Contact:		Height:	Weight:			Male Female		
Allergies:								
Current Medications:								
Other Medical Conditions or Additional Comments:								
Medical History Related to IV Insertion (e.g. lymph nodes or mastectomy):								
DIAGNOSIS								
Patient Diagnosis & ICD-10: G30.0 - Alzheimer's disease with early onset G30.1 - Alzheimer's disease with late onset G30.8 - Other Alzheimer's disease G30.8 - Other Alzheimer's disease G31.84 - Mild cognitive impairment								
Prescriber must indicate the following requirements have been met to confirm diagnosis & that Patient has evidence of AD neuropathology & has been assessed for baseline ARIA risk via MRI:								
Amyloid pathology confirmed via: Amyloid PET Scan - OR - CSF Analysis - OR - Blood plasma Result: Amyloid positive Amyloid negative (<i>Kisunla</i> ™ is not a treatment option for this Patient, if checked)						Date:		
Recent MRI obtained prior to initiating Kisunla™ (including FLAIR and T2/GRE or SWI) to assess ARIA risk Prescriber has verified that this Patient does not have evidence of prior ARIA-H						Date:		
Completion of cognitive assessment type: MMSE MoCA CDR Other: Score:						Date:		
Completion of functional assessment type: FAQ FAST Other:					Date:			
Results for ApoETesting						Date:		
Completion of CMS approved CED registry (only required for Patients with Medicare) ClinicalTrials.gov Registry Number: NCTSubmission Number (if applicable):					CED Submission Date:			
Note: MRIs must be obtained prior to initial infusion to assess ARIA risk. During treatment, conduct an ARIA monitoring MRI before Infusions 2, 3, 4 and 7 and if symptoms consistent with ARIA occur.								
PROVIDER INFORMATION								
Physician Name:		Lic.#:			DEA #:			
Practice Name:		NPI#:						
Address:	Address:				City/State/Zi	rte/Zip:		
Office Contact:		Phone:		Fax:				
Supervisory Physician (if applicable):								
PLEASE ATTACH								
Patient demographics & front/back copy of all insurance cards (prescription & medical) Recent office visit notes, history & physical, lab & pertinent procedure results Current medication list & list of prior medications tried and failed (with dates) Line access documentation/verification if applicable Vaccine status (any vaccination) and documentation of any recent vaccinations Letter of medical necessity if drug dosing or indication is outside of FDA guidelines Letter of medical necessity if drug dosing or indication is outside of FDA guidelines								
NURSING & LAB ORDERS								
Nurse Orders: Nurse to provide assessment, teaching, lab draws, medication administration and vascular access device insertion and/or management per physician orders. Flush Orders: NaCl 0.9% - 5-10mL flush pre and post infusion and as needed Heparin - 10units/mLOR 100units/mL - 3-5mL flush after post-infusion NS flush if indicated to maintain line								
Lab Orders: Lab Date & Frequency:								
PRESCRIPTION ORDERS								
Anaphylaxis Kit: Epinephrine 0.3mg IM as needed Solu-cortef 250mg-500mg IV as needed Solu-Medrol 60mg - 125mg IV as needed (Check all that apply) Diphenhydraminemg IV as needed NS Hydration 500 ml IV over 30 minutes as needed Other Pre-Medications: Acetaminophenmg POminutes prior to infusion Solu-Medrolmg IVminutes prior to infusion						eeded		
(Check all that apply) Diphenhydraminemg POOR IVminutes prior to infusion Other								
Supply Orders: All supplies for vascular access line care, drug administration kit(s), pump, and IV pole will be provided as necessary								
PRODUCT			SCRIPTION IN	FORM.	ATION		REFILLS	
Is this a first dose? Ye	s No If No, when was last dose given	?	When is patient d	ue for next o	dose?			
KISUNLA	Induction: 700mg IV infusion via	gravity 0R	pump over 30 minutes	every 4 wee	ks x 3 doses		NONE	
	Maintenance: 1400mg IV infusion via	gravity 0R	- pump over 30 minu	tes every 4 v	veeks			
	If missed dose, administer the same dose as soon as possible and continue every 4 weeks. Obtain MRI prior to 2nd, 3rd, 4th, and 7th infusions. MRI results must be performed and cleared by MD to proceed to next infusion.							
OTHER	Fire to English Tury drift and					1	NONE	
By signing this form and utilizing our services, you are authorizing Amerita to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies.								



Print Name





Date

AME EVI_KISUNLA REFER 9.24

Print Name

Date

Prescriber's Signature Substitution Permitted